RET, ROS1 and ALK fusions in lung cancer


Through an integrated molecular- and histopathology-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion–positive and 13 ROS1-fusion–positive adenocarcinomas, including for unidentified fusion partners for ROS1. In addition, we discovered previously unidentified kinase fusions that may be promising for molecular-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain containing 6 (CCDC6)-RET, in 14 adenocarcinomas. A multivariate analysis of 1,116 adenocarcinomas containing these 71 kinase-fusion–positive adenocarcinomas identified four independent factors that are indicators of poor prognosis: age ≥50 years, male sex, high pathological stage and negative kinase-fusion status.

DOI: 10.1038/nm.2658

2 Figures and Tables

Citations per Year

1,764 Citations

Semantic Scholar estimates that this publication has 1,764 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Takeuchi2012RETRA, title={RET, ROS1 and ALK fusions in lung cancer}, author={Kengo Takeuchi and Manabu Soda and Yuki Togashi and Ritsuro Suzuki and Seiji Sakata and Satoko Hatano and Reimi Asaka and Wakako Hamanaka and Hironori Ninomiya and Hirofumi Uehara and Young Lim Choi and Yukitoshi Satoh and Sakae Okumura and Ken Nakagawa and Hiroyuki Mano and Yuichi Ishikawa}, journal={Nature Medicine}, year={2012}, volume={18}, pages={378-381} }